Sample-size calculations for multi-group comparison in population pharmacokinetic experiments

Pharmaceutical Statistics

Volumn 9, Issue 4, 2010, Pages 255-268

  Ogungbenro, Kayode ^a   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

mixed effects modelling; multi group comparison; population pharmacokinetics; power; sample size

Indexed keywords

ARTICLE; CALCULATION; COMPUTER PROGRAM; DRUG DOSE REGIMEN; HYPOTHESIS; LINEAR SYSTEM; MATHEMATICAL MODEL; NONLINEAR SYSTEM; PARAMETER; PHARMACOKINETICS; POPULATION PHARMACOKINETICS; RANDOMIZATION; SAMPLE SIZE; SIMULATION; STUDY DESIGN;

HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; POPULATION; SAMPLE SIZE;

EID: 78650660944     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.388     Document Type: Article

References (26)

1. Aarons L,. Population pharmacokinetics: theory and practice. British Journal of Clinical Pharmacology 1991; 32: 669-670.
2. Sheiner LB, Rosenberg B, Marathe VV,. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 1977; 5: 445-479.
3. Vozeh S, Steimer JL, Rowland M, Morselli P, Mentré F, Balant LP, Aarons L,. The use of population pharmacokinetics in drug development. Clinical Pharmacokinetics 1996; 30: 81-93.
4. Beal SL, Sheiner LB,. Estimating population kinetics. Critical Reviews in Biomedical Engineering 1982; 8: 195-222.
5. White DB, Walawander CA, Liu DY, Grasela TH,. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. Journal of Pharmacokinetics and Biopharmaceutics 1992; 20: 295-313.
6. Mandema JW, Verotta D, Sheiner LB,. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. Journal of Pharmacokinetics and Biopharmaceutics 1992; 20: 511-528.
7. FDA. Guidance for industry, pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labelling, 1998.
8. Lee PI,. Design and power of a population pharmacokinetic study. Pharmaceutical Research 2001; 18: 75-82.
9. Kowalski KG, Hutmacher MM,. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Statistics in Medicine 2001; 20: 75-91.
10. Kang D, Schwartz JB, Verotta D,. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetic models. Statistics in Medicine 2004; 23: 2551-2566.
11. Kang D, Schwartz JB, Verotta D,. Sample size computations for PK/PD population models. Journal of Pharmacokinetics and Pharmacodynamics 2005; 32: 685-701.
12. Ogungbenro K, Aarons L, Graham G,. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments. Journal of Biopharmaceutical Statistics 2006; 16: 135-150.
13. Retout S, Comet E, Samson A, Mentré F,. Design in nonlinear mixed effects models: Optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. Statistics in Medicine 2007; 26: 5162-5179.
14. Rochon J,. Application of GEE procedures for sample size calculations in repeated measures experiments. Statistics in Medicine 1998; 17: 1643-1658.
15. Liang KY, Zeger SL,. Longitudinal data-analysis using generalized linear-models. Biometrika 1986; 73: 13-22.
16. Zeger SL, Liang KY, Albert PS,. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 1049-1060.
17. Mentré F, Mallet A, Baccar D,. Optimal design in random-effects regression models. Biometrika 1997; 84: 429-442.
18. Retout S, Mentré F,. Optimization of individual and population designs using Splus. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30: 417-443.
19. Retout S, Mentré F,. Further developments of the fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. Journal of Biopharmaceutical Statistics 2003; 13: 209-227.
20. Retout S, Duffull S, Mentré F,. Development and implementation of the population fisher information matrix for the evaluation of population pharmacokinetic designs. Computer Methods and Programs in Biomedicine 2001; 65: 141-151.
21. Gagnon R, Leonov S,. Optimal population designs for PK models with serial sampling. Journal of Biopharmaceutical Statistics 2005; 15: 143-163.
22. Davidian M, Giltinan DM,. Nonlinear Models for Repeated Measurement. Chapman and Hall: London, 1995.
23. Wahlby U, Jonsson EN, Karlsson MO,. Assessment of actual significance levels for covariate effects in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics 2001; 28: 231-252.
24. Wahlby U, Jonsson EN, Karlsson MO,. Commentary on significance levels for covariate effects in NONMEM-Reply. Journal of Pharmacokinetics and Pharmacodynamics 2002; 29: 411-412.
25. Beal SL,. Commentary on significance levels for covariate effects in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics 2002; 29: 403-410.
26. Atkinson AC, Donev AN,. Optimum Experimental Designs. Oxford University Press: Oxford, 1992.